In a quiet laboratory in Heidelberg, a team of researchers has assembled the most comprehensive picture yet of how the trillions of bacteria living in our guts relate to colorectal cancer—and what they found could reshape how we detect and understand the disease.
By reanalyzing data from 27 previous studies, comprising 6,779 gut microbiome profiles, an international team from the Mi-EOCRC consortium has identified a microbial signature consistently present in people with colorectal cancer, regardless of where they live, which testing method was used, or how old they were when diagnosed. The research, published in Cell Host & Microbe and led by the Zeller and Zimmermann groups at EMBL Heidelberg, also examined 906 intestinal tissue samples to compare stool-based signals with microbes found directly within tumors.
For years, scientists have observed differences between the microbiomes of colorectal cancer patients and healthy individuals. But smaller studies using different methodologies often contradicted one another, making it hard to know which findings were truly meaningful. This new meta-analysis overcomes those limitations by applying machine learning algorithms trained to distinguish cancer-associated microbiomes from healthy ones—a tool that worked reliably across datasets it had never seen before.
"The strength of this study is its comprehensiveness," said Georg Zeller, Visiting Team Leader at EMBL Heidelberg and Professor at Leiden University Medical Center. "We combined stool and tissue comparisons, dietary data, taxonomic analysis down to bacterial strains, and functional analysis of virulence factors."
The results revealed something striking: microbes enriched in tumor tissue closely mirrored the signature found in fecal samples. Even more remarkably, cancer-associated microbes were detectable in early-stage tumors—a finding that suggests microbiome changes may appear very early in disease development.
"These results suggest that colorectal cancer-associated changes in the microbiome may appear early in disease development and raise the question of how the tumor shapes the microbiome and how the microbes impact the tumor microenvironment," explained Michael Zimmermann, Group Leader at EMBL Heidelberg.
The study also found that the cancer-associated microbiome signature correlated with lower dietary fiber intake, hinting at potential preventive strategies. While precancerous adenomas proved more difficult to detect through stool samples alone—likely because smaller or upstream tumors release fewer microbial markers into stool—this robust signature represents a significant step forward in understanding how gut bacteria and colorectal cancer interact.
For patients and physicians, the findings offer hope that microbiome-based diagnostics could one day complement existing screening methods, particularly for catching cancers in their earliest, most treatable stages.